Baidu
map

Cell:复旦大学研究院解析骨髓造血关键蛋白TET2三维结构

2013-12-12 佚名 健康报

复旦大学生物医学研究院研究员徐彦辉课题组经4年多研究,首次成功解析了哺乳动物骨髓造血关键蛋白TET2的三维结构。该成果对研究多种疾病的发病机制,尤其对血液肿瘤(如髓系白血病)治疗性药物开发有重大意义。相关论文日前在线发表在国际学术期刊《细胞》杂志上。 哺乳动物TET蛋白家族有3个成员,即TET1蛋白、TET2蛋白和TET3蛋白,在哺乳动物发育和骨髓造血等关键生命过程

复旦大学生物医学研究院研究员徐彦辉课题组经4年多研究,首次成功解析了哺乳动物骨髓造血关键蛋白TET2的三维结构。该成果对研究多种疾病的发病机制,尤其对血液肿瘤(如髓系白血病)治疗性药物开发有重大意义。相关论文日前在线发表在国际学术期刊《细胞》杂志上。

哺乳动物TET蛋白家族有3个成员,即TET1蛋白、TET2蛋白和TET3蛋白,在哺乳动物发育和骨髓造血等关键生命过程中扮演着至关重要的角色。TET蛋白丧失功能会导致各种疾病(尤其是血液肿瘤)的发生。人体DNA上有一种甲基化特殊标记,该标记对哺乳动物发育和癌症发生有重要作用。甲基化标记位点排列正确的话,生命运动运转正常;标记位点紊乱,就会导致各种疾病,尤其是血液肿瘤疾病的发生。有趣的是,哺乳动物在发育过程中的各阶段,会根据需要自动调节DNA上的甲基化标记。科学界对甲基化标记是如何被“添加”到DNA上的已有定论,但甲基化标记是如何被“去除”的,则一直是谜。2009年,有科学家发现,哺乳动物体内的TET蛋白对甲基化标记的“去除”起关键作用。

徐彦辉课题组运用X射线晶体学等研究方法,获得了TET2蛋白和DNA两者结合在一起的三维结构,结果发现TET2蛋白非常“聪明”,能够自动识别、找到甲基化标记,并会把甲基化标记修饰过的DNA翻转到TET2蛋白的内部,又在内部铁离子等帮助下,产生氧化反应后,将这些标记逐步“添加”到DNA甲基化标记上。

研究发现,TET1蛋白在急性髓细胞性白血病中与致癌蛋白MLL发生融合后,会导致哺乳动物罹患癌症。后研究发现,血液肿瘤患者血液中含有多种TET2蛋白突变,且突变率很高,正是这些突变影响了TET2蛋白的活性,导致它“消极怠工”,最终引发疾病。而TET2蛋白的“同胞兄弟”TET1,在急性髓细胞性白血病形成过程中“过分活跃”,扮演了“致病帮凶”的角色。

原文出处:

Hu L, Li Z, Cheng J, Rao Q, Gong W, Liu M, Shi YG, Zhu J, Wang P, Xu Y.Crystal Structure of TET2-DNA Complex: Insight into TET-Mediated 5mC Oxidation.Cell. 2013 Dec 3. pii: S0092-8674(13)01469-4. doi: 10.1016/j.cell.2013.11.020. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2011155, encodeId=90122011155f0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sat Aug 02 11:13:00 CST 2014, time=2014-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734792, encodeId=e08b1e3479242, content=<a href='/topic/show?id=a1a819e6783' target=_blank style='color:#2F92EE;'>#三维结构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19767, encryptionId=a1a819e6783, topicName=三维结构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf33833612, createdName=ailian1213, createdTime=Mon Aug 11 06:13:00 CST 2014, time=2014-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958969, encodeId=3834195896949, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Oct 08 13:13:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868729, encodeId=a67b1868e2978, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 12 14:13:00 CST 2014, time=2014-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027598, encodeId=4dd1202e59848, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Nov 03 02:13:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672717, encodeId=474f16e2717f1, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Sun Aug 17 10:13:00 CST 2014, time=2014-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446526, encodeId=a1e6144652653, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Sat Dec 14 01:13:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494472, encodeId=2be814944e251, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sat Dec 14 01:13:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538427, encodeId=23a9153842e8c, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Sat Dec 14 01:13:00 CST 2013, time=2013-12-14, status=1, ipAttribution=)]
    2014-08-02 yhy100200
  2. [GetPortalCommentsPageByObjectIdResponse(id=2011155, encodeId=90122011155f0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sat Aug 02 11:13:00 CST 2014, time=2014-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734792, encodeId=e08b1e3479242, content=<a href='/topic/show?id=a1a819e6783' target=_blank style='color:#2F92EE;'>#三维结构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19767, encryptionId=a1a819e6783, topicName=三维结构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf33833612, createdName=ailian1213, createdTime=Mon Aug 11 06:13:00 CST 2014, time=2014-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958969, encodeId=3834195896949, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Oct 08 13:13:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868729, encodeId=a67b1868e2978, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 12 14:13:00 CST 2014, time=2014-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027598, encodeId=4dd1202e59848, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Nov 03 02:13:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672717, encodeId=474f16e2717f1, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Sun Aug 17 10:13:00 CST 2014, time=2014-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446526, encodeId=a1e6144652653, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Sat Dec 14 01:13:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494472, encodeId=2be814944e251, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sat Dec 14 01:13:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538427, encodeId=23a9153842e8c, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Sat Dec 14 01:13:00 CST 2013, time=2013-12-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2011155, encodeId=90122011155f0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sat Aug 02 11:13:00 CST 2014, time=2014-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734792, encodeId=e08b1e3479242, content=<a href='/topic/show?id=a1a819e6783' target=_blank style='color:#2F92EE;'>#三维结构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19767, encryptionId=a1a819e6783, topicName=三维结构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf33833612, createdName=ailian1213, createdTime=Mon Aug 11 06:13:00 CST 2014, time=2014-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958969, encodeId=3834195896949, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Oct 08 13:13:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868729, encodeId=a67b1868e2978, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 12 14:13:00 CST 2014, time=2014-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027598, encodeId=4dd1202e59848, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Nov 03 02:13:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672717, encodeId=474f16e2717f1, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Sun Aug 17 10:13:00 CST 2014, time=2014-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446526, encodeId=a1e6144652653, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Sat Dec 14 01:13:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494472, encodeId=2be814944e251, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sat Dec 14 01:13:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538427, encodeId=23a9153842e8c, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Sat Dec 14 01:13:00 CST 2013, time=2013-12-14, status=1, ipAttribution=)]
    2014-10-08 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=2011155, encodeId=90122011155f0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sat Aug 02 11:13:00 CST 2014, time=2014-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734792, encodeId=e08b1e3479242, content=<a href='/topic/show?id=a1a819e6783' target=_blank style='color:#2F92EE;'>#三维结构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19767, encryptionId=a1a819e6783, topicName=三维结构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf33833612, createdName=ailian1213, createdTime=Mon Aug 11 06:13:00 CST 2014, time=2014-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958969, encodeId=3834195896949, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Oct 08 13:13:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868729, encodeId=a67b1868e2978, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 12 14:13:00 CST 2014, time=2014-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027598, encodeId=4dd1202e59848, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Nov 03 02:13:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672717, encodeId=474f16e2717f1, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Sun Aug 17 10:13:00 CST 2014, time=2014-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446526, encodeId=a1e6144652653, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Sat Dec 14 01:13:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494472, encodeId=2be814944e251, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sat Dec 14 01:13:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538427, encodeId=23a9153842e8c, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Sat Dec 14 01:13:00 CST 2013, time=2013-12-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2011155, encodeId=90122011155f0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sat Aug 02 11:13:00 CST 2014, time=2014-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734792, encodeId=e08b1e3479242, content=<a href='/topic/show?id=a1a819e6783' target=_blank style='color:#2F92EE;'>#三维结构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19767, encryptionId=a1a819e6783, topicName=三维结构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf33833612, createdName=ailian1213, createdTime=Mon Aug 11 06:13:00 CST 2014, time=2014-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958969, encodeId=3834195896949, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Oct 08 13:13:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868729, encodeId=a67b1868e2978, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 12 14:13:00 CST 2014, time=2014-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027598, encodeId=4dd1202e59848, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Nov 03 02:13:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672717, encodeId=474f16e2717f1, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Sun Aug 17 10:13:00 CST 2014, time=2014-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446526, encodeId=a1e6144652653, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Sat Dec 14 01:13:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494472, encodeId=2be814944e251, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sat Dec 14 01:13:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538427, encodeId=23a9153842e8c, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Sat Dec 14 01:13:00 CST 2013, time=2013-12-14, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2011155, encodeId=90122011155f0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sat Aug 02 11:13:00 CST 2014, time=2014-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734792, encodeId=e08b1e3479242, content=<a href='/topic/show?id=a1a819e6783' target=_blank style='color:#2F92EE;'>#三维结构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19767, encryptionId=a1a819e6783, topicName=三维结构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf33833612, createdName=ailian1213, createdTime=Mon Aug 11 06:13:00 CST 2014, time=2014-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958969, encodeId=3834195896949, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Oct 08 13:13:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868729, encodeId=a67b1868e2978, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 12 14:13:00 CST 2014, time=2014-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027598, encodeId=4dd1202e59848, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Nov 03 02:13:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672717, encodeId=474f16e2717f1, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Sun Aug 17 10:13:00 CST 2014, time=2014-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446526, encodeId=a1e6144652653, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Sat Dec 14 01:13:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494472, encodeId=2be814944e251, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sat Dec 14 01:13:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538427, encodeId=23a9153842e8c, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Sat Dec 14 01:13:00 CST 2013, time=2013-12-14, status=1, ipAttribution=)]
    2014-08-17 hongbochen
  7. [GetPortalCommentsPageByObjectIdResponse(id=2011155, encodeId=90122011155f0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sat Aug 02 11:13:00 CST 2014, time=2014-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734792, encodeId=e08b1e3479242, content=<a href='/topic/show?id=a1a819e6783' target=_blank style='color:#2F92EE;'>#三维结构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19767, encryptionId=a1a819e6783, topicName=三维结构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf33833612, createdName=ailian1213, createdTime=Mon Aug 11 06:13:00 CST 2014, time=2014-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958969, encodeId=3834195896949, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Oct 08 13:13:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868729, encodeId=a67b1868e2978, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 12 14:13:00 CST 2014, time=2014-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027598, encodeId=4dd1202e59848, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Nov 03 02:13:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672717, encodeId=474f16e2717f1, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Sun Aug 17 10:13:00 CST 2014, time=2014-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446526, encodeId=a1e6144652653, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Sat Dec 14 01:13:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494472, encodeId=2be814944e251, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sat Dec 14 01:13:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538427, encodeId=23a9153842e8c, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Sat Dec 14 01:13:00 CST 2013, time=2013-12-14, status=1, ipAttribution=)]
    2013-12-14 neurowu
  8. [GetPortalCommentsPageByObjectIdResponse(id=2011155, encodeId=90122011155f0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sat Aug 02 11:13:00 CST 2014, time=2014-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734792, encodeId=e08b1e3479242, content=<a href='/topic/show?id=a1a819e6783' target=_blank style='color:#2F92EE;'>#三维结构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19767, encryptionId=a1a819e6783, topicName=三维结构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf33833612, createdName=ailian1213, createdTime=Mon Aug 11 06:13:00 CST 2014, time=2014-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958969, encodeId=3834195896949, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Oct 08 13:13:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868729, encodeId=a67b1868e2978, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 12 14:13:00 CST 2014, time=2014-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027598, encodeId=4dd1202e59848, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Nov 03 02:13:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672717, encodeId=474f16e2717f1, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Sun Aug 17 10:13:00 CST 2014, time=2014-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446526, encodeId=a1e6144652653, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Sat Dec 14 01:13:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494472, encodeId=2be814944e251, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sat Dec 14 01:13:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538427, encodeId=23a9153842e8c, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Sat Dec 14 01:13:00 CST 2013, time=2013-12-14, status=1, ipAttribution=)]
    2013-12-14 俅侠
  9. [GetPortalCommentsPageByObjectIdResponse(id=2011155, encodeId=90122011155f0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sat Aug 02 11:13:00 CST 2014, time=2014-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734792, encodeId=e08b1e3479242, content=<a href='/topic/show?id=a1a819e6783' target=_blank style='color:#2F92EE;'>#三维结构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19767, encryptionId=a1a819e6783, topicName=三维结构)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf33833612, createdName=ailian1213, createdTime=Mon Aug 11 06:13:00 CST 2014, time=2014-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958969, encodeId=3834195896949, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Oct 08 13:13:00 CST 2014, time=2014-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868729, encodeId=a67b1868e2978, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 12 14:13:00 CST 2014, time=2014-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027598, encodeId=4dd1202e59848, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Nov 03 02:13:00 CST 2014, time=2014-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672717, encodeId=474f16e2717f1, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Sun Aug 17 10:13:00 CST 2014, time=2014-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446526, encodeId=a1e6144652653, content=<a href='/topic/show?id=2c001e30276' target=_blank style='color:#2F92EE;'>#TET2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17302, encryptionId=2c001e30276, topicName=TET2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aeee5221880, createdName=neurowu, createdTime=Sat Dec 14 01:13:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494472, encodeId=2be814944e251, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Sat Dec 14 01:13:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538427, encodeId=23a9153842e8c, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Sat Dec 14 01:13:00 CST 2013, time=2013-12-14, status=1, ipAttribution=)]
    2013-12-14 saikp

相关资讯

Lancet Oncol:Tosedostat可有效治疗复发或难治性急性髓细胞性白血病老年患者

治疗组患者的总体生存期的Kaplan-Meier曲线 Tosedostat是一种新型的口服氨基肽酶抑制剂,既往研究已证实其在复发或难治性急性髓细胞性白血病老年患者中的临床作用。来自美国休斯敦 Anderson 肿瘤中心的Jorge Cortes等的这一研究旨在比较两种不同剂量的Tosedostat治疗方案对上述患者的疗效,他们的研究结果发表在Lancet Oncol 3月最新的在线期刊上。

Cancer Cell:抑制HLX基因改善急性髓细胞性白血病的治疗

Yeshiva大学爱因斯坦医学院的科学家们在人类急性髓细胞性白血病(AML),一种罕见的、致命的癌症中获得了突破性研究进展,这可能意味着人们向新的急性髓细胞性白血病治疗方案又近了一步。他们的研究结果发表在今天的Cancer Cell杂志上。 细胞生物学和医学助理教授、医学博士Ulrich Steidl说:我们已经发现名为HLX的基因在白血病小鼠模型中白血病干细胞中异常高表达。 (基因表达的过程是

JCI:CDK1或成为急性髓细胞性白血病治疗新靶标

急性髓细胞性白血病(acute myeloid leukemia, AML, 也译作急性髓系白血病或急性髓性白血病)是成年人身上常见的一种白血病,其特征在于癌性骨髓细胞(cancerous bone marrow cell)异常增殖。在急性髓细胞性白血病中,人们观察到的的最为流行的突变之一就是一种被称作FLT3受体的蛋白受体存在激活突变。FLT3突变体被认为能够激活促进癌症生长的信号途径。 来自

Baidu
map
Baidu
map
Baidu
map